Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
Sign Up to like & getrecommendations! Published in 2024 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.70030
Abstract: Upadacitinib, a Janus kinase (JAK) inhibitor, has been approved by the FDA to treat various autoimmune conditions. This study assessed its adverse events by analyzing reports from the FDA Adverse Event Reporting System (FAERS). read more here.
Keywords: upadacitinib pharmacovigilance; event; adverse event; assessment upadacitinib ... See more keywords